Home / Research library / Tirzepatide
Tirzepatide: molecular data, studies & sources
Tirzepatide is catalogued here as a research compound. This profile brings together the molecular source record, selected indexed publications and available supplier comparisons. Evidence for a named substance does not authenticate a commercial product.
Compiled by PeptideTech Editors · Sources checked · Selected bibliography, not a systematic review
Molecular formula, weight & structure
- Molecular formula (MF)
- C225H348N48O68
- Molecular weight (MW)
- 4813 g/mol
- PubChem compound ID
- 156588324
- Record title
- Tirzepatide
Values describe the selected PubChem molecular entity. Counterions, salt forms, hydration and sequence changes can alter the supplied material. Confirm the exact identity against the supplier specification.
Source: PubChem CID 156588324 · retrieved 2026-09-21
Chemical identifiers and source data
- IUPAC name
- (2S)-2-[[20-[[(5S)-6-[[(2S,3S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[2-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[(2S)-2-[(2S)-2-[(2S)-2-[[(2S)-1-amino-3-hydroxy-1-oxopropan-2-yl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidine-1-carbonyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-2-oxoethyl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-5-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-2-methylpropanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-2-methylpropanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]-6-oxohexyl]amino]-20-oxoicosanoyl]amino]-5-[2-[2-[2-[2-[2-(carboxymethoxy)ethoxy]ethylamino]-2-oxoethoxy]ethoxy]ethylamino]-5-oxopentanoic acid
- InChIKey
- AAPYRSPHYSKGIS-MCNPHUAVSA-N
- SMILES
- CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)NCC(=O)NCC(=O)N4CCC[C@H]4C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N5CCC[C@H]5C(=O)N6CCC[C@H]6C(=O)N7CCC[C@H]7C(=O)N[C@@H](CO)C(=O)N)NC(=O)[C@H](CCCCNC(=O)CCCCCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)NCCOCCOCC(=O)NCCOCCOCC(=O)O)C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)C(C)(C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H](CC8=CC=C(C=C8)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC9=CC=CC=C9)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@H](CC1=CC=C(C=C1)O)N
Identifiers
- PubChem CID
- 156588324
- ChEMBL ID
- CHEMBL4297839
- InChIKey
- AAPYRSPHYSKGIS-MCNPHUAVSA-N
- Wikidata
- Q108324770
Other names and development codes: BG-121 · LY-3298176
Calculated molecular descriptors
| Monoisotopic (exact) mass | 4810.5249 Da |
|---|---|
| Heavy atoms | 341 |
| Hydrogen-bond donors | 58 |
| Hydrogen-bond acceptors | 65 |
| Rotatable bonds | 163 |
| Topological polar surface area | 1789.6 Ų |
| Calculated logP (Crippen) | -12.10 |
| Rings | 10 |
| Stereocenters | 39 |
| Formal charge | 0 |
Computed with RDKit from the published SMILES (Crippen logP, topological polar surface area). Calculated descriptors are not measured properties of a supplied batch.
US regulatory status & drug development
Tirzepatide is the active ingredient of FDA-approved medicines that Drugs@FDA lists as marketed prescription products (checked October 7, 2026): MOUNJARO (NDA 215866, approved May 13, 2022) and ZEPBOUND (NDA 217806, approved November 8, 2023). Research-labelled Tirzepatide listings are not MOUNJARO or ZEPBOUND and are not FDA-approved drugs.
| Medicine | Application | Sponsor | First approval | Marketing status |
|---|---|---|---|---|
| MOUNJAROtirzepatide | NDA 215866DailyMed label: Mounjaro · 2026-08-27DailyMed label: MOUNJARO · 2026-07-29 | ELI LILLY AND CO | Prescription | |
| ZEPBOUNDtirzepatide | NDA 217806DailyMed label: Zepbound · 2026-08-28 | ELI LILLY AND CO | Prescription |
An FDA approval covers a defined medicine, formulation and labelled use. It does not extend to research-labelled material sold under the same compound name. Identity basis: Same active ingredient name (tirzepatide).
Source: Drugs@FDA via openFDA (application records; DailyMed label set IDs) · checked . openFDA data are not intended for clinical decisions.
Drug development record (ChEMBL)
Harmonized drug-development record from ChEMBL. The highest clinical stage is the furthest stage reached, as recorded by ChEMBL; it can lag regulatory approvals, and it is not an approval of a research-supplier product.
- ChEMBL ID
- CHEMBL4297839
- Modality
- Protein / peptide
- Highest clinical stage
- Approved in at least one jurisdiction (ChEMBL phase 4)
- Record name
- TIRZEPATIDE
Mechanism of action
- Gastric inhibitory polypeptide receptor agonist · target: Gastric inhibitory polypeptide receptor (GIPR)
- Glucagon-like peptide 1 receptor agonist · target: Glucagon-like peptide 1 receptor (GLP1R)
Synonyms, codes and trade names
- Trade and brand names (Drugs@FDA)
- MOUNJARO · MOUNJARO (AUTOINJECTOR) · MOUNJARO KWIKPEN · ZEPBOUND · ZEPBOUND (AUTOINJECTOR) · ZEPBOUND KWIKPEN
- Synonyms and development codes
- BG-121 · LY-3298176 · LY3298176 · Tirzepatide
Identity check: PubChem / GSRS ChEMBL cross-reference and an exact name match. Source: ChEMBL CHEMBL4297839 (EMBL-EBI, CC BY-SA 3.0) · retrieved 2026-10-07
Registered clinical trials
Studies registered on ClinicalTrials.gov that list Tirzepatide as an intervention. Studies that only measure the molecule as a biomarker, or use it only as a comparator or background arm for another drug, are excluded. A registration describes a planned or completed protocol; it does not report a result. Active studies are listed first.
38 registered studies matched, 38 currently active or recruiting.
- By highest phase
- Phase 4 · 9Phase 3 · 6Phase 2 · 14Phase 1 · 2Early phase 1 · 1Not applicable · 6
- By registry status
- Not Yet Recruiting · 20Recruiting · 16Enrolling By Invitation · 2
| Study | Phase · status | Conditions | Sponsor · size |
|---|---|---|---|
| Effects of Tirzepatide on Gut Microbiota and Gastrointestinal Function After Drug Withdrawal in Obese PatientsNCT07847515 · start 2027-02-01 · primary completion 2027-06 | Not applicableNot Yet Recruiting | Obesity / Overweight | Nanjing First Hospital, Nanjing Medical University80 participants |
| Tirzepatide in Women With Obesity and Endometrial Intra-epithelial Neoplasia or Grade 1 Endometrial CancerNCT07078838 · start 2027-01 · primary completion 2029-03 | Phase 2Not Yet Recruiting | Endometrial Cancer · Endometrial Intraepithelial Neoplasia · Grade 1 Endometrial Endometrioid Carcinoma | UNC Lineberger Comprehensive Cancer Center40 participants |
| Efficacy of Tirzepatide for Weight Management in Patients With Suboptimal Weight Loss After Bariatric Surgery: A Randomized, Double-Blind, Placebo-Controlled Clinical TrialNCT07829198 · start 2027-01 · primary completion 2028-12 | Phase 3Not Yet Recruiting | Obesity | Universidade do Porto70 participants |
| Tirzepatide for the Treatment of Concurrent Type 1 Diabetes and Overweight or ObesityNCT06180616 · start 2026-12 · primary completion 2028-12 | Phase 2Not Yet Recruiting | Type 1 Diabetes Mellitus · Overweight and Obesity | Royal North Shore Hospital40 participants |
| A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial CancerNCT07349641 · start 2026-11-01 · primary completion 2029-10-31 | Phase 2Not Yet Recruiting | Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia · FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma | National Cancer Institute (NCI)55 participants |
| Trial of Tirzepatide for the Treatment of Cannabis Use DisorderNCT07468552 · start 2026-11-15 · primary completion 2028-03-15 | Phase 2Not Yet Recruiting | Cannabis Use Disorder | National Institute on Drug Abuse (NIDA)100 participants |
| Tirzepatide and Levonorgestrel IUD Therapy for EIN and Early-Stage Endometrial CancerNCT07812636 · start 2026-11-01 · primary completion 2028-05-01 | Early phase 1Not Yet Recruiting | Grade 1 Endometrial Endometrioid Carcinoma · Endometrial Intraepithelial Neoplasia · Metabolic Comorbidities | Milton S. Hershey Medical Center15 participants |
| Clinical and Neurobehavioral Changes With Weight Loss Drug Discontinuation and ReinitiationNCT07387796 · start 2026-10 · primary completion 2028-02 | Not applicableRecruiting | Drug Discontinuation · Substance Use Disorders · Eating Behavior Changes · Tirzepatide | The University of Texas at Dallas40 participants |
| Tirzepatide Versus Positive Airway Pressure for the Treatment of Obstructive Sleep Apnoea: A Randomised Comparative Effectiveness TrialNCT07846865 · start 2026-10-01 · primary completion 2028-12-01 | Phase 2 / Phase 3Not Yet Recruiting | Sleep Apnoea · Obesity & Overweight · Sleep Apnea Syndrome, Obstructive | Woolcock Institute of Medical Research256 participants |
| Effect of Tirzepatide on Recurrence of Atrial Fibrillation After Catheter Ablation in Obese PatientsNCT07715929 · start 2026-09-01 · primary completion 2029-09-01 | Phase 4Not Yet Recruiting | Atrial Fibrillation · Obesity & Overweight · Catheter Ablation | Yunlong Wang710 participants |
Show 28 more registered studies
| Study | Phase · status | Conditions | Sponsor · size |
|---|---|---|---|
| Tirzepatide in Thrombectomy-Treated Acute Ischemic Stroke: A Randomized TrialNCT07734792 · start 2026-09-20 · primary completion 2028-05-31 | Phase 2 / Phase 3Not Yet Recruiting | Acute Ischemic Stroke (AIS) | yifang zhu726 participants |
| Tirzepatide for Ileal Pouch-anal Anastomosis (IPAA) and Chronic High Bowel Frequency (I8F-NS-X008)NCT07756359 · start 2026-09 · primary completion 2027-09 | Phase 4Not Yet Recruiting | Pouch, Ileal · Pouches, Ileoanal · Bowel Diseases, Inflammatory | University of North Carolina, Chapel Hill20 participants |
| A Study of Tirzepatide (LY3298176) in Participants With Type 1 Diabetes Mellitus and Overweight or ObesityNCT07803744 · start 2026-09-11 · primary completion 2026-12 | Phase 1Recruiting | Diabetes Mellitus, Type 1 · Overweight · Obesity | Eli Lilly and Company18 participants |
| Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS)NCT07817875 · start 2026-09 · primary completion 2029-12 | Phase 3Not Yet Recruiting | Obesity | Eli Lilly and Company150 participants |
| Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or ObeseNCT06732245 · start 2026-08-15 · primary completion 2027-08-15 | Phase 2Not Yet Recruiting | Obesity and Overweight | Biomed Industries, Inc.224 participants |
| Tirzepatide in Idiopathic Intracranial Hypertension TrialNCT07191873 · start 2026-08-25 · primary completion 2027-08 | Phase 4Recruiting | Idiopathic Intracranial Hypertension (IIH) | Duke University60 participants |
| Incretin Therapies in Obesity-related HFpEFNCT07554638 · start 2026-08-07 · primary completion 2029-04 | Phase 4Recruiting | Heart Failure, Diastolic · Heart Failure With Preserved Ejection Fraction · Obesity | Columbia University50 participants |
| Tirzepatide on Atrial Fibrillation Recurrence After Catheter Ablation in Patients With Obesity and HFpEFNCT07630454 · start 2026-08-01 · primary completion 2029-08-01 | Phase 4Not Yet Recruiting | Atrial Fibrillation · Heart Failure With Preserved Ejection Fraction (HFpEF) · Tirzepatide | Yunlong Wang602 participants |
| Tirzepatide in the Treatment of Cannabis Use DisorderNCT07671248 · start 2026-08-01 · primary completion 2028-07-31 | Phase 3Not Yet Recruiting | Cannabis Use Disorder, Moderate · Cannabis Use Disorder, Severe | McMaster University15 participants |
| A Randomized, Double-blind, Placebo-controlled Study Evaluating the Effect of LAE102 Injection in Combination With Tirzepatide on Body in Obese ParticipantsNCT07671391 · start 2026-08 · primary completion 2027-07 | Phase 2Not Yet Recruiting | Obesity Adult Onset | Shanghai Zhongshan Hospital60 participants |
| Clinical Study of Local and Systemic Biological Impact of GLP1/GIP-Receptor Agonists in Patients With Breast Cancer: The CLARA TrialNCT07676331 · start 2026-08-01 · primary completion 2028-03-01 | Phase 2Not Yet Recruiting | Hormone-receptor-positive Breast Cancer · Early Breast Cancer | Universitaire Ziekenhuizen KU Leuven168 participants |
| An Open-Label Tirzepatide Trial for Comorbid Obesity and Stimulant Use DisorderNCT07693608 · start 2026-08-19 · primary completion 2030-02-01 | Phase 2Enrolling By Invitation | Obesity · Methamphetamine Use Disorder · Cocaine Use Disorder · Stimulant Use Disorders | University of Texas Southwestern Medical Center45 participants |
| Efficacy, Safety, and Treatment Satisfaction of Once-Weekly Tirzepatide in Obese Type 2 Diabetic PatientsNCT07728318 · start 2026-08-12 · primary completion 2027-01-12 | Not applicableNot Yet Recruiting | Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight | Akhtar Saeed Medical and Dental College52 participants |
| Acute Metabolic Effects of Tirzepatide in Type 1 DiabetesNCT06820281 · start 2026-07-07 · primary completion 2027-12-31 | Phase 2Recruiting | Type 1 Diabetes Mellitus | Victor Chang Cardiac Research Institute44 participants |
| Tirzepatide Following Adrenalectomy in Mild Autonomous Cortisol SecretionNCT07573163 · start 2026-07-27 · primary completion 2028-07-31 | Phase 2Recruiting | Mild Autonomous Cortisol Secretion (MACS) · Adrenalectomy; Status | Alaa Sada34 participants |
| Effect of Tirzepatide on Diabetic Peripheral Sensorimotor NeuropathyNCT07706088 · start 2026-07 · primary completion 2028-07-01 | Phase 4Not Yet Recruiting | Neuropathy, Small Fiber · Diabete Mellitus | Post Graduate Institute of Medical Education and Research, Chandigarh40 participants |
| Tirzepatide's Role in Postmenopausal HR+ Breast Cancer SurvivorsNCT07257484 · start 2026-06-08 · primary completion 2027-12-03 | Phase 4Recruiting | Obesity (Disorder) · Breast Cancer | Weill Medical College of Cornell University30 participants |
| Tirzepatide to Reduce rEcurrence And Burden After Ablation of Atrial FibrillationNCT07382024 · start 2026-06-16 · primary completion 2027-12-31 | Not applicableNot Yet Recruiting | Atrial Fibrillation Ablation · Persistent Atrial Fibrillation · Obesity & Overweight | National Taiwan University Hospital200 participants |
| Multi-Site Trial of Tirzepatide for Smoking CessationNCT07602699 · start 2026-06-05 · primary completion 2028-03 | Phase 2Recruiting | Smoking Cessation · Smoking Behaviors | University of Southern California300 participants |
| Tirzepatide's Effects on Epigenetic Aging and Metabolic Restoration in Virally Suppressed People With HIVNCT07707778 · start 2026-06-25 · primary completion 2027-12 | Phase 4Enrolling By Invitation | Human Immunodeficiency Virus (HIV) · Metabolic Dysfunction Associated Steatotic Liver Disease · Dyslipidaemia · Diabetes Mellitus · Obesity & Overweight · Metabolic Syndrome | National Taiwan University Clinical Trial Center60 participants |
| A Clinical Trial Using Tirzepatide to Help Adults With Type 1 Diabetes Automatically Control Their Blood SugarNCT07284511 · start 2026-05-19 · primary completion 2028-01 | Phase 2 / Phase 3Recruiting | Type 1 Diabetes · Type 1 Diabetes Mellitus · T1D · T1DM · T1DM - Type 1 Diabetes Mellitus | McGill University Health Centre/Research Institute of the McGill University Health Centre105 participants |
| A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLDNCT07527910 · start 2026-05-22 · primary completion 2030-03-15 | Phase 2Recruiting | Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | Regeneron Pharmaceuticals204 participants |
| Tirzepatide s Dopaminergic Effects in Alcohol Use Disorders (AUD)NCT07559500 · start 2026-05-20 · primary completion 2031-12-31 | Phase 1Recruiting | Alcohol Use Disorder (AUD) | National Institute on Alcohol Abuse and Alcoholism (NIAAA)176 participants |
| Tirzepatide Titration to Reduce Side Effects in Individuals With ObesityNCT07574723 · start 2026-05-15 · primary completion 2029-05-15 | Not applicableRecruiting | Obesity | Dasman Diabetes Institute68 participants |
| GLP-1 Therapy After Bariatric Surgery in Chinese Patients With ObesityNCT07633639 · start 2026-05-01 · primary completion 2028-05-01 | Not applicableRecruiting | Obesity | China-Japan Friendship Hospital200 participants |
| Effects of Tirzepatide on Muscle and Vascular Health in Obese Older AdultsNCT06811324 · start 2026-04-01 · primary completion 2027-04-01 | Phase 2Recruiting | Obesity Prevention · Sarcopenia in Elderly · Cardiovascular Function · GLP - 1 · Weight Loss | The University of Texas Health Science Center at San Antonio20 participants |
| The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With ObesityNCT07218445 · start 2026-04-08 · primary completion 2027-09-18 | Phase 4Recruiting | Obesity · Menopause Hot Flashes | Mayo Clinic40 participants |
| Resistance Exercise and Incretin Mimetic for Cardiometabolic Health in Survivors of ALL With ObesityNCT07228741 · start 2026-04-23 · primary completion 2027-11 | Phase 2Recruiting | Acute Lymphoblastic Leukemia · Obesity | St. Jude Children's Research Hospital20 participants |
Registry check 2026-10-09 · Run this search on ClinicalTrials.gov
Human intervention studies
Selected studies in which participants received Tirzepatide, with their indexed or reviewed study type. Check the original article for the formulation, population and controls. Studies that only measured the molecule, or used it as a comparator, are listed separately below and are not counted as intervention studies.
- Human study · PubMed trial index Compound given to participants
Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity.
Malhotra A, Grunstein RR, Fietze I et al. · The New England journal of medicine · 2024
PMID 38912654 · DOI: 10.1056/NEJMoa2404881
- Human study · PubMed trial index Compound given to participants
Tirzepatide Once Weekly for the Treatment of Obesity.
Jastreboff AM, Aronne LJ, Ahmad NN et al. · The New England journal of medicine · 2022
PMID 35658024 · DOI: 10.1056/NEJMoa2206038
- Human study · PubMed trial index Compound given to participants
Tirzepatide for Obesity Treatment and Diabetes Prevention.
Jastreboff AM, le Roux CW, Stefanski A et al. · The New England journal of medicine · 2025
PMID 39536238 · DOI: 10.1056/NEJMoa2410819
- Human study · PubMed trial index Compound given to participants
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.
Aronne LJ, Sattar N, Horn DB et al. · JAMA · 2024
PMID 38078870 · DOI: 10.1001/jama.2023.24945
- Human study · PubMed trial index Compound given to participants
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.
Packer M, Zile MR, Kramer CM et al. · The New England journal of medicine · 2025
PMID 39555826 · DOI: 10.1056/NEJMoa2410027
- Human study · PubMed trial index Compound given to participants
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
Frías JP, Davies MJ, Rosenstock J et al. · The New England journal of medicine · 2021
PMID 34170647 · DOI: 10.1056/NEJMoa2107519
- Human study · PubMed trial index Compound given to participants
Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.
Loomba R, Hartman ML, Lawitz EJ et al. · The New England journal of medicine · 2024
PMID 38856224 · DOI: 10.1056/NEJMoa2401943
Preclinical research, reviews & other publications
Animal studies, laboratory experiments, reviews and other indexed papers answer different questions. A review is secondary evidence; a case report does not estimate how often an outcome occurs.
- Review · secondary evidence
Tirzepatide: A Review in Type 2 Diabetes.
France NL, Syed YY · Drugs · 2024
PMID 38388874 · DOI: 10.1007/s40265-023-01992-4
Tirzepatide supplier sources
Scientific sources describe molecules and experiments. The commercial links below identify recorded supplier packages. A publication or chemical database entry does not verify the seller, purity, sterility or contents of a lot. Some links are affiliate links; see our disclosure.
Tirzepatide for sale: compare prices, sizes and forms from every tracked supplier →
| Supplier | Recorded packages | Example source listing |
|---|---|---|
| Blank PeptidesUSD | 10mg Vial · 30mg Vial2 recorded offers | 10mg Vial · $89.00Stale observation · Checked Sep 30, 2026Supplier listing, Tirzepatide 10mg Vial, Blank Peptides, opens in a new tab |
| American PeptidesUSD | 10mg Vial · 30mg Vial · 60mg Vial · 20mg Vial · 100mg Vial5 recorded offers | 10mg Vial · $100.00Checked Nov 6, 2026Supplier listing, Tirzepatide 10mg Vial, American Peptides, opens in a new tab |
| Amino ClubUSD | 30mg Vial · 60mg Vial2 recorded offers | 30mg Vial · $59.99Stale observation · Checked Oct 14, 2026Supplier listing, Tirzepatide 30mg Vial, Amino Club, opens in a new tab |
| Nova Peptide SupplyUSD | 10mg Vial · 30mg Vial · 60mg Vial · 100mg Vial4 recorded offers | 10mg Vial · $69.99Checked Nov 6, 2026Supplier listing, Tirzepatide 10mg Vial, Nova Peptide Supply, opens in a new tab |
| LA PeptidesUSD | 15mg Vial · 30mg Vial2 recorded offers | 15mg Vial · $99.99Checked Nov 3, 2026Supplier listing, Tirzepatide 15mg Vial, LA Peptides, opens in a new tab |
Reference sources & further reading
- PubChem compound record 156588324 — chemical identity and structure.
- ChEMBL drug record CHEMBL4297839 — development stage, mechanism and synonyms.
- Drugs@FDA: NDA 215866 — US approval record for a medicine with the same active ingredient.
- Drugs@FDA: NDA 217806 — US approval record for a medicine with the same active ingredient.
- Wikipedia: Tirzepatide — Background encyclopedia; not a primary clinical source.
The citations above link directly to publication records. Encyclopedia links are background reading and are not used to establish clinical effectiveness.
Search for additional research
These links run searches; their results have not been individually reviewed and can include unrelated compounds.
Research information is not a dosing guide or a recommendation for personal use. Study findings are specific to the formulation, population and methods tested. Read our source and correction policy.
Related research profiles
Cagrilintide
C194H312N54O59S2
4409 g/mol · PubChem CID 171397054
5 selected publications · 4 human intervention studies · 40 registered trials
Protein / peptide · highest stage: Phase 3
Eloralintide
Molecular identity needs further verification
4 selected publications · 3 human intervention studies · 22 registered trials
Liraglutide
C172H265N43O51
3751 g/mol · PubChem CID 16134956
7 selected publications · 4 human intervention studies · 33 registered trials
US: active ingredient of an FDA-approved medicine · Drugs@FDA
Protein / peptide · highest stage: Approved in at least one jurisdiction (ChEMBL phase 4)
Mazdutide
C207H317N45O65
4476 g/mol · PubChem CID 167312357
7 selected publications · 6 human intervention studies · 40 registered trials
Protein / peptide · highest stage: Phase 3
Orforglipron Capsules
C48H48F2N10O5
883.0 g/mol · PubChem CID 137319706
8 selected publications · 6 human intervention studies · 40 registered trials
Small molecule · highest stage: Phase 3
Retatrutide
C221H342N46O68
4731 g/mol · PubChem CID 171390338
9 selected publications · 7 human intervention studies · 34 registered trials